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Background: Intravenous iron polymaltose (IPM) is commonly utilised in pregnancy when 
oral treatment is not tolerated or where rapid replenishment of iron stores is required, but data 
on use in pregnancy is scarce. Aim: To examine the use, safety and efficacy of intravenous 
IPM in pregnancy. Methods: Retrospective cohort study of pregnant women administered 
intravenous IPM between January 2014 and January 2016 at a Tertiary teaching hospital in 
Adelaide, Australia. Data on maternal characteristics, intravenous iron infusion details, and 
haematological parameters were collected from case notes and electronic records. Main 
outcome measures included indication for intravenous iron infusion, prevalence of infusion 
reactions, change in haemoglobin, and correction of anaemia prior to delivery. Results: 
Intravenous IPM was administered in 213 pregnancies, 62.0% of women with iron deficiency 
anaemia (IDA) and the remainder (38.0%) with non-anaemic iron deficiency. Adverse drug 
reactions (ADRs) occurred in 24% of women, of which 32% required infusion cessation. 
Anaemia was still present at delivery among 7%, and 17% of women with mild, and 
moderate/severe anaemia respectively. Approximately 1 in 5 anaemic women received an IV 
IPM dose below that recommended by the local guideline, particularly in women with a BMI 
≥25 kg/m2 compared with <25 kg/m2 (30.9% vs. 6.3%; p<0.001). Doses ‘at recommended’ 
resulted in a greater increase in haemoglobin from treatment until delivery than doses ‘below 
recommended’ (adjusted beta coefficient 8.4 g/L; 95% CI 2.7 to 14.1 g/L). Conclusion: 
Intravenous IPM is effective in treating IDA in pregnancy but is associated with a high 










Iron deficiency represents the most widespread nutritional deficiency globally and is the 
leading cause of anaemia during pregnancy.1 Anaemia is estimated to affect 38% of 
pregnancies worldwide and is associated with a significantly increased risk of perinatal 
morbidity and mortality.1,2 Improvements in haematological status during pregnancy are 
associated with reduced risk of blood loss during delivery, enhanced compensatory response 
to blood loss during delivery, and improved iron status in the postpartum period.3  
 
Intravenous (IV) iron is commonly utilised when oral treatment is not tolerated or where 
rapid replenishment of iron stores is required. The most common types of IV iron utilised in 
pregnancy include iron polymaltose (IPM), ferric carboxymaltose and iron sucrose. These 
preparations significantly differ in some key aspects such as the maximum dose that can be 
administered in a single infusion, the number of infusions required to provide the total dose, 
total infusion time and cost, with IPM being the only type that can be utilised to provide 
complete iron replacement in a single infusion. Despite the commonality of use, few studies 
have investigated the use of IPM in pregnancy, including a total of just 164 women.4-6 Given 
the limited number of clinical studies on IPM in pregnant women and the routine use of this 
formulation in our clinical practice setting, this study aimed to examine its use, safety and 
efficacy in the management of iron deficiency in pregnancy. 
 
Methods 




This study was approved by the Southern Adelaide Local Health Network and University of 
South Australia Human Research Ethics Committee (46.16 – HREC/16/SAC/53; ID 
0000035537) 
 
Study Design and Setting 
Retrospective cohort study of all pregnant women receiving IV IPM between January 1st, 
2014 and January 31st, 2016 at Flinders Medical Centre (FMC) in Adelaide, South Australia. 
FMC is a tertiary level teaching hospital with more than 3,000 births each year. Women were 
identified from electronic hospital pharmacy dispensing records as receiving IPM during 
pregnancy. Antenatal care, including the investigation and management of anaemia in 
pregnancy, is provided according to the South Australian Perinatal Practice Guidelines. This 
includes routine complete blood examination at booking and at 28 weeks’ gestation, with iron 
studies undertaken using a targeted approach of at risk women. 
 
Outcome Measures 
Relevant data were collected from hard copy medical case notes and electronic pathology 
records. A standardised electronic data collection tool was used to collect patient 
demographics, obstetric and medical history, infusion related data, haematological data, iron 
studies, and perinatal outcomes.  
 
Use Evaluation 
Women were initially classified according to the presence or absence of anaemia at the time 
of IV IPM infusion (Haemoglobin <105 g/L after the first trimester7), then further classified 
according to the severity of anaemia, either mild (Haemoglobin 100-104 g/L), moderate 
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(Haemoglobin 90-99 g/L), or severe (Haemoglobin <90 g/L). The presence of iron deficiency 
was determined according to a serum ferritin <30 mcg/L or transferrin saturation ≤16%.8 The 
dose of IPM prescribed was compared to that recommended by the local hospital guideline, 
which recommends calculating the dose based on the following equation: Iron Dose = Weight 
x (Target haemoglobin – Current haemoglobin) x 0.24 + 500 mg.9 The guideline recommends 
a target haemoglobin of 150 g/L, but it does not specify which weight to use when calculating 
the dose (i.e. whether to use pre-pregnancy or current weight). In order to evaluate the 
appropriateness of prescribed iron doses, the expected IV iron dose was first calculated based 
on the woman’s haemoglobin deficit and current weight. To allow for rounding and minor 
variation in dosing weights, 200 mg was subtracted from this expected value. This figure was 
then compared with the actual dose prescribed. Based on this comparison the doses were then 
classified as being either ‘At Recommended Dose’ or ‘Below Recommended Dose’.  
 
Safety Measures 
Adverse drug reactions (ADRs) were classified as either local reactions, occurring at or near 
the injection site, or systemic reactions which include any other reactions regardless of 
severity. Documentation of infusion rate modification, infusion termination or any 
medications used to manage reactions in the case notes were used to assess the impact of the 
experienced ADR. Significance of reactions leading to infusion termination were further 
analysed based on recommencement status: infusions recommenced on the same or an 
alternate day and infusions that were completely ceased.  
 
Efficacy Measures 
Response to IV iron was evaluated by exploring changes in haemoglobin from immediately 
prior to IV iron infusion to 2–4 weeks post-treatment, and immediately prior to delivery. 
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Women were classified as having treatment success if they had a haemoglobin increase of 20 
g/L during the relevant time period. Anaemia status at 2-4 weeks post-infusion and 
immediately prior to delivery were also examined. Efficacy of IV iron based on changes in 
haemoglobin was examined only among those women with confirmed IDA.  
 
Statistical Analysis 
Data Analyses were undertaken using Stata SE 14 (Stata, College Station, TX, USA). 
Continuous data were compared using the Student’s t-test or paired t-test, while categorical 
data were compared using Chi-squared test or Fisher’s exact test as appropriate. Adjusted 
differences between groups with respect to continuous (i.e. haemoglobin change) outcomes 
were compared using a linear regression analysis. Analyses were adjusted for possible 
confounders including gestation at the time of infusion, haemoglobin status prior to infusion, 




IV Iron Use 
Following linkage of the pharmacy dispensing records and perinatal statistics database, a total 
of 247 women were identified as receiving intravenous iron. We then excluded 34 women, 31 
who received IV iron in the postnatal period, two who cancelled their appointment and did 
not end up receiving their IV iron despite it being dispensed, and one who was given it 
intramuscularly instead of intravenously. This left a total of 213 pregnancies during which 
IPM was administered intravenously. No women received multiple IV iron infusions during 
pregnancy. Prior to treatment, 132 women (62%) were identified as anaemic (Haemoglobin < 
105 g/L). Of the remaining 81 non-anaemic women, iron studies were available and 
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confirmed iron deficiency (ferritin < 30 mcg/L) in 75 women (93%). Among anaemic 
women, iron studies were available for 124 women (94%) of which 122 (98%) were 
confirmed IDA. A total of 14 women (6%) did not have any data on iron studies prior to 
treatment. 
 
Compared to non-anaemic iron deficient women, a lower proportion of anaemic women were 
Caucasian (66% vs. 82%; P=0.04). Anaemic women also had a later booking gestation (16.8 
weeks versus 14.3; P=0.005) and were more likely to have trialled oral iron therapy prior to 
IV iron treatment (82% vs. 59%; P<0.001) (Table 1). Mean gestation at treatment was 33.5 
weeks and 32.6 weeks for the IDA and non-anaemia iron deficiency groups. The median 
prescribed intravenous iron dose was 1000 mg (Range: 600 – 1500 mg) and 1400 mg (Range: 
800 – 2000 mg) for women with non-anaemic iron deficiency and IDA respectively. 
Evaluation of the prescribed doses against the dose recommended in the local hospital 
clinical guideline demonstrated that a similar proportion of doses were in accordance with the 
recommended guideline dose in women with non-anaemic iron deficiency and IDA 
respectively (86% versus 81%; p=0.311).  
 
When stratified according to maternal BMI, among women with IDA, 6% (n=4/64) with a 
BMI < 25 kg/m2 compared to 31% (n=21/68) with a BMI ≥ 25 kg/m2 received a dose below 
recommended (p<0.001). No such difference was seen among women with non-anaemic iron 
deficiency, with 12% (n=4/34) of women with a BMI < 25 kg/m2 compared to 15% (n=7/47) 
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Overall, 50/213 women (23.5%) experienced an ADR of which 8 (16%) were local infusion 
site reactions and 43 (86%) were systemic reactions (n=1 experienced both a local and a 
systemic reaction) (Figure 1). Treatment was ceased in 16/213 women (8%) due to 
intolerable adverse events. Of these 16 women, the infusion was recommenced on the same 
day for 8 (50%) women of which 1 required infusion rate modification. For 2/16 (13%) other 
women, the infusion was recommenced on a separate day with premedication (cetirizine 
10mg administered in both women and additional hydrocortisone 250 mg intravenously in 
one) of which 1 had their infusion commenced at a slower rate. The remaining 6/16 (38%) 
women ceased treatment completely. Rate modification was also required in one woman 
without cessation of treatment at any point. In total, 23/50 (46%) women experiencing an 
ADR required medical treatment to manage the symptoms.  
 
Most commonly reported reactions were local reactions (painful or swollen infusion site) 
(n=8; 4%), or systematic reactions including headache (n=8; 4%), and symptomatic 
hypotension (n=8; 4%) (Table 2). One woman experienced a severe anaphylactic reaction 
accompanied with wheezing, chest tightness and elevated blood pressure which required 
complete treatment cessation. There was no statistically significant association between the 
likelihood of an ADR occurrence and potential influencing factors including the dose 
administered (High [> 1000 mg]: 25% versus Low [≤ 1000 mg]: 21%; p=0.722), previously 
documented maternal allergies or adverse drug reactions (Allergy history: 25% versus No 
Allergy History: 23%; p=0.735), anaemia status (IDA: 26% versus Non-Anaemic Iron 
Deficiency: 20%; p=0.405), anaemia severity (Non-Anaemic Iron Deficiency: 20%, Mild 
Anaemia: 24%, Moderate Anaemia: 27%, and Severe Anaemia: 24%; p=0.739) or maternal 
BMI (Underweight: 40%, Normal Weight: 21%, Overweight: 21%, Obese: 26%; p=0.391). 
 




Haemoglobin levels at delivery were available for 118 women (89%) in the IDA group and 
73 women (90%) in the non-anaemic iron deficient group. Significant increases in 
haemoglobin were evident from prior to infusion until delivery among all anaemia severity 
levels (all p<0.001), with the largest increase seen among women with severe anaemia 
(Figure 2). The presence of anaemia at delivery was 1% (n=1/73), 7% (n=2/30), 16% 
(n=9/55), and 18% (n=6/33) among women with non-anaemic iron deficiency, mild anaemia, 
moderate anaemia, and severe anaemia respectively that received IV IPM. 
 
When restricted to women with confirmed IDA (n=132), mean change in haemoglobin from 
prior to IV iron infusion until delivery (adjusted beta 7.9 g/L 95% CI 2.2 to 13.7 g/L; n=118) 
was significant greater among those who received the recommended compared to those who 
received a dose below recommended. Compared to women who received a below 
recommended dose of IV iron, women receiving the recommended dose were more likely to 
experience treatment success, defined as a 20 g/L increase in haemoglobin by delivery (62% 
versus 28%; p=0.010), but no difference in the presence of anaemia at the time of delivery 
(Haemoglobin <105 g/L) was evident (13% versus 16.7%; p=0.709). Further, postpartum 
haemorrhage and the requirement for a postnatal blood transfusion occurred in 17% 
(n=18/107) and 8% (n=8/107) compared with 16% (n=4/25) and 4% (n=1/25) of women who 




One pregnancy in the IDA group resulted in a stillbirth, occurring 3 months following IV iron 
administration. The proportions of vaginal delivery (58% versus 50%), elective caesarean 
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section (30% versus 35%), and emergency caesarean section (12% versus 16%) were similar 
between IDA and non-anaemia iron deficiency groups. Similarly, prevalence of induction of 
labour (27% versus 32%), delivery by caesarean section (42% versus 51%), preterm birth 
(15% versus 16%), low birthweight (14% versus 9%), and postpartum haemorrhage (17% 
versus 16%) were similar between the IDA and non-anaemic iron deficiency groups. Median 
[range] for gestation (39 [28-41] weeks versus 39 [30-41] weeks) and birthweight (3343 
[1275-4745] grams versus 3420 [1230-4705] grams) were also similar between IDA and non-
anaemia iron deficiency groups. Overall, the median (range) number of days from IV iron 
administration to delivery was 29 (1-149) days.  
 
Discussion 
While the use of IV IPM was associated with significant improvements in haematological 
parameters, it was also associated with a much higher prevalence of adverse reactions then 
previously reported in the published literature, affecting approximately 1 in 4 women.  
Overall, IV IPM was highly effective in raising haemoglobin levels by time of delivery 
resulting in resolution of anaemia in the vast majority of pregnant women. These findings are 
consistent with those from previously published studies.4-6 Furthermore, it is evident that 
anaemia was resolved in a similar proportion of women who received a dose equal to or 
above recommended and those who received a dose below recommended. However, the 
degree of correction varied significantly as women who received a dose equal to or above 
recommended were more likely to have achieved a successful haemoglobin response at 
delivery than women given a dose lower than recommended. Consequently the mean 
haemoglobin at delivery was also significantly different among the two groups. Low 
haemoglobin level at delivery is associated with increased perinatal morbidity and mortality; 
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hence, adequate restoration of levels by the time of delivery is vital for optimum perinatal 
outcomes.  
 
The prevalence of adverse reactions identified in this study (23.5%) was much higher than 
the 0% to 5% prevalence reported in the literature. When restricted to those considered 
moderate-severe, 32 women (15%) experienced an ADR requiring treatment cessation, rate 
modification, or medical treatment of symptoms. Singh et al. reported no (0%) adverse 
reactions among a total of 50 exposed women; however, all women were pre-treated with 
25mg of intramuscular promethazine.5 Similarly, Sogbanmu et al. observed an ADR 
prevalence of 4.5% among 22 women, while all women again received pre-medication with 
50mg of intramuscular promethazine.6 In contrast, a recent Australian study by Khalafallah et 
al. examining the use of IV IPM did not administer pre-medication, but reported a similarly 
low prevalence of ADRs (2.2%) among 92 women.4 Observed ADRs were urticarial 
reactions of which 100% required treatment cessation. While it is possible that factors such as 
pre-medication may have influenced the observed difference in ADRs, these have not been 
universally employed in previous studies. Therefore, other factors such as staff awareness of 
ADRs and the requirement to monitor women receiving IV iron for ADRs as part of local 
clinical guidelines at our hospital may explain the higher prevalence. Such a high prevalence 
of ADRs lends support towards consideration and use of alternative formulations of IV iron 
such as ferric carboxymaltose, which has been increasingly studied in pregnancy, does not 
require a test dose, and has been associated with a much lower risk of ADRs.10  
 
The high prevalence of use of IV IPM in the management of non-anaemic iron deficiency 
was unexpected, with no clinical studies to guide appropriate use of IV iron for this 
indication. There is evidence that low iron stores in early pregnancy has a negative impact on 
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pregnancy outcomes, with babies of women with non-anaemic iron deficiency weighing on 
average 192 grams less than those of women with normal iron stores.11 While a recent 
clinical practice survey of health care professionals highlighted strong interest in the 
identification and management of non-anaemic iron deficiency in pregnancy, clinicians had 
reservations on the use of intravenous iron for treatment.12 Overall, the impact and 
subsequent treatment of non-anaemic iron deficiency in pregnancy is poorly understood and 
represents a clear evidence-practice gap for future research. 
 
Approximately 1 in 5 prescribed doses were not in accordance with the locally recommended 
guideline dose for managing iron deficiency anaemia, increasing to 1 in 3 prescribed doses 
being lower than that recommended by the guidelines for women who were overweight or 
obese. This is potentially suggestive of the clinician’s decision to cap or modify the dose after 
its calculation, or use an alternative dosing weight such as ideal body weight, potentially due 
to concerns relating to overdosing these women. However, there are no published studies 
exploring optimal dosing of IV iron in pregnancy, nor studies exploring optimal dosing of IV 
iron among adults who are overweight/obese. Anecdotally, it has been suggested that dosing 
for women who are overweight/obese should be based on ideal body weight, rather than 
current weight, but the optimal approach remains to be determined. Counteracting this are 
potential concerns relating to the unknown harms of administering excess IV iron, with any 
potential negative consequences on the fetus remaining undetermined. Supporting such 
potential concerns are data associating adverse pregnancy outcomes with high haemoglobin 
concentrations.13-14 Therefore, studies investigating both maternal and neonatal outcomes in 
this population according to different dosing strategies is urgently needed to optimise IV iron 
dosing. 
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This study has a number of strengths. With a total of 213 women, this is the largest study 
evaluating the use of IV IPM in pregnancy, compared to the cumulative total of 164 women 
included in previous publications.4-6 Case notes for 100% of women identified as being 
dispensed IV IPM were reviewed and a variety of resources were used, including paper-based 
and electronic records, to capture data as much complete data as possible on these women.  
 
The limitations of this study are consistent with its retrospective nature. We were reliant on 
information obtainable from electronic or paper-based records and on tests ordered by 
clinicians as part of routine clinical care. For example, data on haemoglobin values at 
delivery were obtainable in 90% of women compared with only 54% of women at 2 to 4 
weeks following the IV iron infusion. Furthermore, iron studies were not available for 7% of 
women, making it impossible to determine if they were truly iron deficient. In addition, we 
did not have data regarding oral iron use following IV iron administration. Lastly, while the 
high prevalence of identified adverse events suggests that poor documentation was unlikely 




Intravenous IPM is effective in the treatment of iron deficiency anaemia in pregnancy; 
however, a higher rate of adverse drug reactions was noted (23.5%) in this study compared to 
that previously published in the literature. Despite success of treatment, a significant number 
of women received a dose lower than recommended by local clinical guidelines, with the 
dose received associated with significant differences in haematological response, highlighting 
the need of IV iron dose optimisation especially in overweight or obese women.   
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(n = 81) 
Iron Deficiency 
Anaemia 
(n = 132) 
P-value 
Age (Years), mean (SD) 29.5 (6.7) 28.6 (5.5) 0.258 
Ethnicity, n (%) 
    Caucasian 
    Aboriginal 
    Asian 












Booking BMI (kg/m2), mean 
(SD) 
27.3 (6.6) 26.6 (6.8) 0.484 
Parity > 1, n (%) 59 (73%) 92 (70%) 0.624 
Previous Pregnancy < 1 Year 
Ago, n (%) 
6 (7%) 8 (6%) 0.700 
Oral Iron Trial, n (%) 48 (59%) 107 (82%) < 0.001 
Oral Iron Intolerance, n (%) 21 (26%) 27 (21%) 0.328 
Gestation at Treatment 
(Weeks), mean (SD) 
32.6 (5.1) 33.5 (3.7) 0.144 
Plurality (fetal count > 1), n 
(%) 
1 (1.2%) 10 (7.6%) 0.055 
Booking Gestation (Weeks), 
mean (SD) 
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Table 2. Description of adverse drug reactions (ADRs) to intravenous iron polymaltose 
administration and their occurrence 
 
Adverse Drug Reactions n (%) 
Local Reactions 
Painful, swollen infusion site 8 (16%) 
Systemic Reactions 
Headache  8 (16%) 
Symptomatic Hypotension  8 (16%) 
Back pain 7 (14%) 
Heartburn 6 (12%) 
Chest tightness 5 (10%) 
Dyspnoea  5 (10%) 
Nausea  4 (8%) 
Heat sensation  4 (8%) 
Chest pain  4 (8%) 
Tachycardia  4 (8%) 
Rash 2 (4%) 
Vomiting  2 (4%) 
Blurry vision 1 (2%) 
Itchiness  1 (2%) 
Muscle pain  1 (2%) 
Tingling lips 1 (2%) 
Decrease in oxygen saturation 
(Asymptomatic) 
1 (2%) 
Elevated Blood Pressure 1 (2%) 
Anaphylaxis  1 (2%) 
Total number of women experiencing 
an ADR 
50* 
*total number of reactions experienced do not add up to 
the total number of women as some may have 








Figure 2. Mean (±SD) haemoglobin change across pregnancy according to anaemia severity 
at the time of intravenous iron polymaltose infusion 
 
